Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

20163,613 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: The Lancet

Volume 389, Issue 10064, pp. 56-66

Field-Weighted Citation Impact: 162.43